Hemispherx BioPharma Inc.
(Public, AMEX:HEB)
At approximately 3:30pm EST, 5/29/09, StocksHaven Investments began the call conference scheduled with Chairman & CEO of Hemispherx BioPharma Inc., Dr. William Carter. The basis interview was with regards to TheStreet.com’s Adam Feuerstein’s recent article, “Hemispherx’s CFS Drug Is a Long Shot“.  The interview was concluded as of 4:00pm EST, 5/29/09. Many [...]

In the latest developments of Hemispherx BioPharma, BioMedReports analyzes and dissects the latest article from TheStreet.com with an interview involving Dr. Carter. If you are an avid fan of Ampligen and have invested in Hemispherx, this read is definitely worth your time.

Article published by M.E. Garza of BioMedReports.com
“What do we think CFS is?” Dr. William [...]

Occasionally StocksHaven Investments will review company websites that in some way fit in with the daily life of an investor. Laptops are seen as an essential tool to any day trader’s lifestyle, so this company was deemed a perfect fit for our next review.

Many private investors have graciously given positive reviews for StocksHaven Investments’ latest conference call with Hemispherx BioPharma (Public, AMEX:HEB). Due to this, a follow up list providing essentials and guidance for successful conference calls seemed like a great idea. So without further adue, here is Michael Vlaicu’s strategies on championing this task:
1. INTRODUCTION Many [...]

So I have recently just made a deal with Questrade, one of the cheapest online discount brokers around. So let me cut right to the chase…

Only $4.95 per trade
No monthly fees!
Min. balance of only $1000
Top notch customer care (phone call takes no more than 2 minutes to be answered)

Ready to retire? Not so fast.

There was a time when people looked forward to their retirement, but it is now a time of dread for many senior citizens. Whilst mortgage and rental costs are often lower for seniors, the cost of gas, electricity, lighting and food actually goes up. In January 2009 The Institute of Fiscal Studies calculated that [...]

Because we all deserve a good laugh after a long days worth of work.

Hemispherx BioPharma Inc.
(Public, AMEX:HEB)
At approximately 4:30pm EST, 5/15/09, StocksHaven Investments began the call conference scheduled with Chairman & CEO of Hemispherx BioPharma Inc., Dr. William Carter. The interview process was a tremendous success and was concluded as of 5:00pm EST, 5/15/09. Many issues and concerns of private individual investors were raised and answered in a [...]

Acadia Pharmaceuticals, Inc.
(Public, NASDAQ:ACAD)
A San Diego drug maker is hoping an infusion of research capital will allow it to continue its work in searching for Parkinson’s disease treatments.
Acadia Pharmaceuticals (NASDAQ:ACAD)‎, which hopes its drug, pimavanserin, will treat Parkinson’s-related psychosis, recently received $30 million from Canadian pharmaceuticals company Biovail Corp. (NYSE: BVF) in a deal that [...]

At this time StocksHaven Investments would like to open and establish the option of submitting your questions, comments and requests you would like to be forward while engaged within the Hemispherx BioPharma, Inc. call conference which is scheduled on May/15/09. Please use the ‘Contant Us‘ tab located in the menu bar.
Any racial, discriminatory, sexually offensive [...]